Clinical Trials Logo

Filter by:
NCT ID: NCT05952466 Completed - COVID-19 Pandemic Clinical Trials

Retinal and Choroidal Microvascular Parameters in School-age Children in a COVID-19 Infection Pandemic Peak in China

Start date: February 1, 2023
Phase:
Study type: Observational

We designed this study to examine whether COVID-19 infection could lead to retinal and choroidal microvascular involvement in school-age children (6-18 years) in a pandemic peak in China.

NCT ID: NCT05952375 Recruiting - Gastric Cancer Clinical Trials

Exploratory Clinical Trial on the Safety, Efficacy, and Pharmacokinetics of XKDCT086 (iPD-1-Claudin18.2-CAR-T) in Claudin 18.2 Positive Advanced Solid Malignant Tumors: a Single Center, Single Arm, Dose-increasing Trial

Start date: March 1, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to assessing the safety and tolerability of XKDCT086 cells against recurrent or refractory solid tumors with Claudin18.2 positivity.This experiment proposes to enroll 9-18 patients, the experimental drug is a chimeric antigen receptor T cell preparation targeting Claudin18.2.

NCT ID: NCT05952154 Recruiting - Clinical trials for Nonobstructive Hypertrophic Cardiomyopathy

Transapical Beating-Heart Septal Myectomy in Patients With Symptomatic Nonobstructive Hypertrophic Cardiomyopathy

Start date: July 2023
Phase: N/A
Study type: Interventional

The primary purpose of this study is to evaluate the feasibility, the safety and the efficacy of the transapical beating-heart septal myectomy for the treatment of nonobstructive hypertrophic cardiomyopathy. This is a prospective, single-arm, single-center study.

NCT ID: NCT05952128 Recruiting - Sarcoma Clinical Trials

Phase Ib/II Study of Fluzoparib in Combination With Dalpiciclib in Patients With Locally Advanced or Metastatic Sarcoma

Start date: July 1, 2023
Phase: Phase 2
Study type: Interventional

This is a single-center, single-arm phase Ib / II clinical trial, which was included with two phase. The main purpose of the phase Ib part was to determine the dose-limiting toxicity ( DLT ), maximum tolerated dose ( MTD ), and recommended dose ( RP2D ) of Fluzoparib combined with Dalpiciclib in patients with locally advanced or metastatic sarcoma. The phase II part is mainly to observe the efficacy and safety of Fluzoparib combined with Dalpiciclib.

NCT ID: NCT05952050 Recruiting - General Anesthesia Clinical Trials

Different Administration Routes of Dexmedetomidine on Postoperative Delirium

Start date: August 1, 2023
Phase: N/A
Study type: Interventional

Intravenous dexmedetomidine has been reported to decrease the occurrence of postoperative delirium (POD) in elderly patients. Nevertheless, some previous studies have indicated that intratracheal dexmedetomidine and intranasal dexmedetomidine are also effective and convenient. The current study aimed to compare the effect of different administration routes of dexmedetomidine on POD in elderly patients.

NCT ID: NCT05952037 Recruiting - Clinical trials for Waldenstrom Macroglobulinemia

Study to Evaluate the Efficacy and Safety of BGB-11417 in Participants With Waldenström's Macroglobulinemia

Start date: September 28, 2023
Phase: Phase 2
Study type: Interventional

This study will evaluate the safety and efficacy of the BCL2 inhibitor BGB-11417 in participants with relapsed/refractory Waldenström's Macroglobulinemia (R/R WM) in 3 cohorts.

NCT ID: NCT05951855 Recruiting - Clinical trials for Acute Myeloid Leukemia (Relapsed/Refractory)

Study of Selinexor Combined With Chidamide in Relapsed/Refractory Acute Leukemia (AML) Patients

Start date: March 1, 2023
Phase: Phase 2
Study type: Interventional

This is a prospective, single-arm, multi-center clinical trial to evaluate the efficacy and safety of selinexor combined with chidamide in the treatment of unfit R/R AML.

NCT ID: NCT05951725 Active, not recruiting - Clinical trials for Diphtheria, Tetanus and Acellular Pertussis

A Clinical Trial of Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed(DTcP)

Start date: August 11, 2023
Phase: Phase 3
Study type: Interventional

The combined pertussis, diphtheria and tetanus vaccine, the first vaccine to be included in the Expanded Programme of Immunization(EPI) of World Health Organization(WHO), has played an important role in the prevention and control of these three infectious diseases. The (diphtheria,tetanus and acellular pertussis combined vaccine,DTaP) vaccine was successfully developed in China in 1993, and its safety and serological effects were confirmed by the observation of human safety, with mild vaccination reactions and good immunization effects.The (Diphtheria-tetanus-component acellular pertussis vaccine, DTcP) vaccine is suitable for immunization against pertussis, diphtheria and tetanus infections in people between 2 and 24 months of age.

NCT ID: NCT05951517 Recruiting - Clinical trials for Gastrointestinal Injury

Mycophenolate Mofetil in Gastrointestinal Henoch-Schonlein Purpura

Start date: January 1, 2023
Phase: N/A
Study type: Interventional

Henoch Schönlein purpura (HSP) is the most common type of vasculitis in children, with an incidence of ~10/100,000, whereas >90% of the patients develop symptoms at <10 years of age. Although HSP is generally a self-limiting disease, it may also lead to severe complications, such as intestinal intussusception, infarction and perforation, as well as end-stage renal disease. The management of HSP includes symptomatic treatment and immunosuppressive therapy in certain patients. Previous retrospective studies have reported that most patients with gastrointestinal (GI) symptoms may benefit from early usage of glucocorticoid, whereas there are still a part of HSP patients with GI did not achieved remission after administering of steroid. Therefore, the aim of the present study was to investigate the clinical features of refractory GI HSP and the clinical outcome of mycophenolate mofetil in these patients.

NCT ID: NCT05951465 Completed - Clinical trials for Autism Spectrum Disorder

Esketamine and Propofol for Children With Autism Spectrum Disorder Undergoing Colonoscopy

Start date: July 20, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to examine the dose-response relationship of esketamine in combination with propofol for children with Autism Spectrum Disorder undering colonoscopy.